
    
      This monocentre, observational study will include pregnant women whom HBV-DNA is > 105 IU/mL.
      HBV MTCT rates will be evaluated, according to the level of HBV-DNA in the women during the
      last three months of pregnancy and at childbirth (between 105 and 108 IU/mL, or > 108 IU/mL),
      and according to the clinical practices of serovaccination in the participating center. The
      evaluation will be based on the rate of HBsAg positivity in infants at 9 months, despite a
      correct immunization at birth. The rate of detectable HBV-DNA will be also evaluated in
      infants at the same date.
    
  